Sequim-Based Financial Advisor Dave Nute Celebrates Milestone of Helping Over 500 Washington Seniors Achieve Retirement Security
Dave Nute integrated approach combines financial planning and strategic mortgage solutions to create sustainable income and long-term security.
Washington, United States, March 22, 2025 -- Dave Nute Sequim, a trusted Sequim-based financial advisor, is proud to announce a significant milestone in his career when helping over 500 Washington seniors recover an average of $120,000 in untapped retirement assets. As a licensed Retirement Income Certified Professional (RICP) and Mortgage Loan Originator, Nute has become a leading resource for seniors seeking financial stability in retirement.
With a rapidly growing senior population in Sequim and across Washington, many retirees face concerns about sustaining their income, affording healthcare, and maintaining their quality of life. Traditional retirement planning often focuses solely on investments and savings, leaving many unaware of alternative strategies that could significantly improve their financial outlook.
Through his hybrid approach, Nute integrates comprehensive financial planning with specialized mortgage solutions, including reverse mortgages, to help seniors maximize their available assets. This strategy ensures retirees can access their home equity wisely while preserving their retirement funds, reducing financial stress, and maintaining their independence.
One of Nute's many success stories includes a retired couple in Sequim. 'As a diabetic, I had been turned down on three different occasions for a long term care policy. Dave found me an annuity policy that gave us 3 times our premium for long term care and if not used, our initial premium would be returned and even better - no monthly premiums. This has been a great relief to my wife and I' - the client shared.
Dave Nute 's unique strategy involves assessing each client's financial situation holistically, factoring in savings, home equity, pensions, Social Security, and investments. The result is to design a comprehensive plan that balances income needs and long-term security. His work with reverse mortgages has been especially impactful, helping seniors convert home equity into a steady source of income without the need to sell their homes.
In addition to retirement planning, Dave Nute Sequim educates seniors about tax strategies, healthcare costs, and Social Security optimization. His client-focused approach has made him a trusted figure in the Sequim community, known for delivering clear, honest advice tailored to each client's needs.
The business aim is to make retirement be a time of comfort and security, not financial stress. The final goal is to help seniors make the most of their assets so they can live with confidence.
Northwest Reverse Mortgage.
About Dave Nute
Dave Nute is a Sequim-based Retirement Income Certified Professional (RICP) and Mortgage Loan Originator with years of experience helping Washington seniors navigate retirement. Nute's expertise has made him a trusted resource for seniors looking to maximize their assets and achieve financial peace of mind.
Contact Info:
Name: Dave Nute
Email: Send Email
Organization: Dave Nute Sequim
Address: 410 Salal Way, Seqium, WA 98382
Phone: 1-800-562-9514
Release ID: 89155874
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 minutes ago
- Yahoo
Missouri Attorney General threatens legal action against 18 hemp companies; more to come
(Rebecca Rivas/The Missouri Independent) Missouri Attorney General Andrew Bailey has sent several cease-and-desist letters to companies selling a hemp product called THCA flower that looks exactly like marijuana flower sold at dispensaries. Bailey's letters threaten legal action, including injunctions, civil penalties and attorney's fees if the companies continue to sell the products. 'When purchasing products, Missourians deserve to know if they are being exposed to dangerous side effects like psychotic episodes, hallucinations or other life-threatening risks,' said Attorney General Bailey in a statement to The Independent. 'We have issued 18 cease and desist letters so far, and more are forthcoming.' Cannabis lobbyist Eapen Thampy said about a dozen smoke shops in St. Louis received the letters, and in some cases, THCA flower makes up 60% to 80% of the companies' inventories. Thampy said he's working with the companies to put together a response to the letters and preparing for potential litigation. The action is the first major move since Bailey created a new specialized unit last fall, with the aim to assist the state's alcohol and tobacco regulators in cracking down on intoxicating hemp products. In September, Bailey vowed his new unit would work with the Missouri Alcohol and Tobacco Control Division to bring legal action against licensees selling unregulated psychoactive cannabis products that violate the Missouri Merchandising Practices Act. 'The ATC will assist by making its investigators available as witnesses for legal proceedings resulting from actionable referrals,' Bailey said in September. 'Our enforcement toolkit will be robust from cease-and-desist letters and investigations to subpoenas and lawsuits to referrals for criminal prosecution where appropriate.' The letters that went out last month state that the companies are 'directed to cease and desist from selling' hemp products that contain more than 0.3% THCA on a dry weight basis. THCA is a naturally abundant cannabinoid that transforms into Delta-9 THC when smoked or heated. However, this is not what an official cease and desist order looks like, said Jefferson City-based attorney Chuck Hatfield. 'It is an informal cease and desist,' Hatfield said. 'It is not a letter that has the force and effect of law. It's more in the nature of a request to stop.' Under state law, if Bailey wanted to issue an official cease and desist order – as he did for Planned Parenthood in March – Hatfield said Bailey would have to issue a notice of intent first. The company would have the right to appeal through an administrative hearing, as well as challenge the order in court. 'But he hasn't done any of that,' Hatfield said. Bailey could also file a lawsuit under Missouri Merchandising Practices Act, and that doesn't require a cease and desist order, he said. Charles Alovisetti, a cannabis attorney with Vincente law firm in Boston, said the lack of a state law to support the action could put Bailey in a tricky spot. 'If the goal is to control THCA flower sales, states should regulate hemp products in their final form, including THCA flower, through clear legislation,' Alovisetti wrote in a LinkedIn post. 'Letters like this may not hold up in court.' For the third year in a row, state lawmakers failed to pass legislation to regulate intoxicating hemp products by the end of the session in May. At issue in Bailey's letters is THCA, which is not intoxicating in its natural state. Most marijuana flower found in dispensaries contains about 20-40% THCA, which would not get a person high if they consumed it without heating it. It has to be smoked to transform it into Delta-9 THC, which produces the desired high for consumers. The process of heating is called decarboxylation. Legal action against THCA hemp flower raises a dizzying debate about distinction between hemp and marijuana under federal law. Cannabis attorney Rod Kight, who has represented hemp businesses in lawsuits nationwide, said Bailey's letter accurately states that the sole distinction between legal hemp and illegal marijuana is the concentration of delta-9 THC, which cannot exceed 0.3% for hemp. The part Bailey gets wrong, Kight said, is claiming that THCA is part of the calculation for determining whether harvested hemp or a hemp product is lawful. 'Given that Missouri law does not address THCA at all, it is clear that the attorney general is relying on recent letters from the DEA in support of its position that the concentration of THCA must be taken into account when determining the legal status of harvested hemp and hemp products,' Kight said. However, he said the U.S. Drug Enforcement Administration's interpretation has caused a lot of confusion. 'Hemp growers must account for THCA before harvesting their hemp crops,' Kight said. 'Thereafter, the THCA concentration does not matter under federal law or the laws of Missouri and the 'post-decarboxylation' test does not apply to harvested hemp or hemp products sold by wholesalers or retailers.' Since the 2018 Farm Bill legalized hemp, botanists have figured out how to breed cannabis plants capable of passing the only federal checkpoint required on hemp plants — a visit from U.S. Department of Agriculture inspectors 30 days before harvest. At that point, the levels of Delta-9 THC and THCA are below the federal threshold, but both increase before being harvested 30 days later. Kight said he believes there's lots of marijuana flower sold in dispensaries that would probably meet this standard of hemp as well. It's a point that's being argued in court, he said. 'THCA is the most abundant cannabinoid that cannabis produces,' he said. 'If there's any cannabinoid that humans have truly ingested for thousands of years, it's THCA. The hemp industry is moving kind of back towards this more natural sort of state of affairs, and I'm very pleased with that.' SUBSCRIBE: GET THE MORNING HEADLINES DELIVERED TO YOUR INBOX
CNBC
18 minutes ago
- CNBC
Ron Insana says Trump's spending bill unlikely to generate the economic boom he promised
As he did in his first term as president, President Donald Trump is once again predicting an economic boom the likes of which the U.S. has never before seen. In reviewing the publicly available economic data since Ronald Reagan, the period in which the U.S. grew the fastest with the most job creation did not occur in Trump's first term and is unlikely to do so in this term, the reasons why to be explained shortly. First, a brief review of recent economic history where the biggest economic boom actually took place. Former President Bill Clinton's eight years in office produced nearly 4% annual growth, over 240,000 jobs added per month and an inflation rate that averaged less than 3%, considered very low for that time. The unemployment rate when Clinton first took office was 7.3% and bottomed at 3.8% by April 2000. By contrast, in Trump's first term, the economy added under 200,000 jobs per month, roughly equal to that of former President Barack Obama, while GDP growth averaged 2.3%, again, roughly equal to Obama's last three years in office, while inflation was less than a quarter percentage point lower than in Obama's second term. (Trump's numbers, of course, were skewed by the Covid crisis, which featured the steepest and shortest recession in U.S. history.) All that leads me to the notion that a boom, the likes of which we have not seen, is unlikely even if the "Big Beautiful Bill" passes through Congress and lands on Trump's desk. And here's why. Nothing new to help growth First, the bill largely extends existing tax rates that were put in place in 2017, without further lowering corporate taxes, as once promised, from 21% to 15%. There are no major additional tax cuts included in the bill. The bill simply makes much of the existing code permanent. No change, no gain. It's true that taxes on tips, overtime and Social Security payments may be eliminated, but that could also lead to employers seeking out ways, in the first two cases anyway, to pay lower wages if tips and overtime go untaxed. Beyond that, there's not much new in the bill that would accelerate economic growth, nor would a failure of the bill's passage lead to a 68% tax increase for everyone in America, as the president has warned . Published analyses have suggested that 68% of Americans could see a 7% increase in their taxes, but not a 68% increase in what they pay. Given the prospects for rising inflation amid recently imposed tariffs, and a subsequent slowing in consumer spending, some of which is already taking place, the economy appears to be downshifting rather than speeding up. Job growth , as we saw on Friday, has moderated for several months in a row and while not reflective of a recession, we're also witnessing a jump in jobless claims, announced layoffs and, according to some published reports, consumers maxing out credit cards to buy the basics. Add to that the reductions in support for the poorest Americans, whether its access to Medicaid or food stamps, and the ingredients for a further slowdown are embedded in the bill, especially for those who can least afford to have government assistance reduced in a meaningful way. Big changes needed The Department of Government Efficiency spending cuts are also affecting government stimulus in so far as key funding in technology, medicine and education are being slashed, threatening the very areas that make the U.S. economy competitive and very much growth-oriented. The bill, by most accounts, also adds from $2.4 trillion to $3.3 trillion to the budget deficit over the next decade. With the current national debt standing at a record $36.2 trillion, higher federal borrowing needs could further push up borrowing costs as investors, especially international ones, now nervous about America's fiscal position could demand higher yields to compensate them for the risk, however unlikely, that the U.S. runs into trouble in paying its bills. During the Clinton administration, tax rates were higher, and yet growth was stronger, 22.7 million jobs were added and the budget deficit turned to surplus by the end of his term. None of those metrics are supported by existing or proposed policy initiatives today. The Clinton boom was second only to that of FDR, whose economy grew strongly as Roosevelt took over, quite literally, at the very bottom of the Great Depression. In modern times, Clinton's economy was stronger than that of any president who came before or after him. None of the policies currently being pursued by this administration offer the same prospects for growth though, even like Clinton, this president has a major technological revolution underway. That big, beautiful bill would require some big, bountiful changes if it hopes to stimulate growth in a way in which all Americans, rather than perhaps a handful of billionaires, will share meaningfully in any future prosperity.
Yahoo
28 minutes ago
- Yahoo
Metsera Announces Positive Phase 1 Data of First-in-Class Once-Monthly Amylin Candidate MET-233i
Placebo-subtracted mean weight loss up to 8.4% at Day 36 19-day observed half-life supports once-monthly dosing as monotherapy and potential first-in-category monthly GLP-1 + Amylin combination Well-tolerated with no safety signals Company to host conference call and webcast today at 8:00 A.M. ET NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR), today announced positive topline data from the Phase 1 clinical trial of MET-233i, an ultra-long acting amylin analog engineered for class-leading durability, potency, and combinability with Metsera's fully-biased monthly GLP-1 receptor agonist candidate, MET-097i. In the study, MET-233i demonstrated up to 8.4% mean placebo-subtracted weight loss at Day 36, a 19-day observed half-life supporting once-monthly dosing, and a favorable tolerability profile with no safety signals. 'We are excited by these impressive results from MET-233i, which demonstrate exceptional efficacy with no safety signals, and enable the potential first monthly multi-NuSH combination,' said Steve Marso, M.D., Chief Medical Officer of Metsera. 'We observed five-week body weight loss comparable to that of leading GLP-1-based medicines, and we identified efficacious starting doses with placebo-like tolerability. These data position MET-233i as a potential best-in-class amylin and support a category-leading profile in combination with MET-097i.' The randomized, placebo-controlled, double-blind Phase 1 trial was designed to evaluate the pharmacokinetics, efficacy, and safety of subcutaneous MET-233i in 80 participants with overweight or obesity without type 2 diabetes. MET-233i was evaluated at single doses from 0.15 mg to 2.4 mg, and multiple doses from 0.15 mg to 1.2 mg given once weekly over five weeks without titration. The trial population was broadly balanced in gender between MET-233i and placebo and had a mean baseline body mass index of approximately 32. Topline results from the Phase 1 trial include: Dose-linear pharmacokinetics with an observed half-life of 19 days from dose to 50% of Cmax. This represents the most durable pharmacokinetic profile of any known amylin analog and supports the potential for once-monthly dosing with simplified titration. MET-233i's exposure profile after multiple doses matched that of MET-097i, supporting combinability as a potential first-in-category once-monthly multi-NuSH combination. These data further substantiate HALO™, Metsera's proprietary, novel peptide stabilization and lipidation platform technology. Body weight loss up to 8.4%. Body weight loss was dose-dependent, ranging up to a placebo-subtracted mean of 8.4% at Day 36 after five weekly doses of 1.2 mg, with individual responses as high as 10.2%. In the single ascending dose (SAD) portion of the trial, substantial weight loss was maintained more than four weeks after dosing, supported by the ultra-long pharmacokinetics observed for MET-233i. Favorable tolerability results. Gastrointestinal adverse events in the multiple ascending dose (MAD) portion of the trial were all mild, dose-dependent, and primarily confined to the first week of dosing, implying rapid onset of tolerance despite a three-fold accumulation of exposure over five weeks. Anticipated starting doses of 0.15 mg and 0.3 mg demonstrated tolerability results comparable to placebo in both the SAD and the MAD portions of the trial. No safety signals. There were no severe or serious adverse events observed in the SAD or MAD portion of the trial to date. 'Amylin agonism has emerged as a central therapeutic mechanism for metabolic diseases, but candidates in development have been limited to weekly dosing,' said Professor Carel le Roux, Director of the Metabolic Medicine Group and Chair in Experimental Pathology at University College Dublin. 'The durability and efficacy of MET-233i in this trial, along with its combinability with Metsera's GLP-1 RA, make it the potential first monthly multi-NuSH combination candidate for patients seeking greater levels of well-tolerated weight loss with a more convenient dosing schedule.'Next StepsBased on these positive topline data, Metsera is rapidly advancing MET-233i as a monotherapy and in combination with MET-097i: An ongoing monotherapy trial evaluates 12 weekly doses of MET-233i with dose titration, followed by an exposure-matched monthly dose at week 13. Topline data from this trial are expected in late 2025. Metsera has extended an ongoing co-administration trial of MET-233i and MET-097i to twelve weeks, with topline data expected by year-end 2025 or early 2026. The Company also expects to report topline clinical data from its ultra-long acting GIP receptor agonist, MET-034i, in combination with MET-097i, in late 2025. We anticipate that MET-034i will be the third peptide engineered with Metsera's HALO™ platform to enter clinical Call and Webcast InformationMetsera will host a conference call and webcast today, June 9, 2025, at 8:00 A.M. Eastern Time to discuss the Phase 1 clinical trial of MET-233i. A live webcast of the call and a replay will be available on the Events page in the Investors & News section of the Metsera website at To access the call by phone, participants should visit this link to receive dial-in details: About MET-233i MET-233i is an ultra-long acting, subcutaneously injectable monthly amylin analog engineered for class-leading durability, potency, and combinability in solution with Metsera's fully-biased, ultra-long acting GLP-1 RA candidate MET-097i, with matched solubility parameters and observed half-lives. MET-233i is being explored in clinical studies as a monotherapy and in combination with MET-097i. Metsera is developing the combination of MET-233i and MET-097i via the FDA biologic pathway with the intent to pursue the combination's regulatory approval in the United States under a Metsera's HALO™ peptide stabilization and lipidation platformHALO™ is Metsera's novel peptide stabilization and lipidation platform technology that enables peptides to bind simultaneously to albumin and to a drug target, designed to facilitate a half-life approaching that of albumin and exceeding that of other NuSH peptides. This ultra-long half-life may enable monthly dosing, improved tolerability, and improved Metsera, is a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases. Metsera is advancing a broad portfolio of oral and injectable incretin, non-incretin and combination therapies with potential best-in-class profiles to address multiple therapeutic targets and meet the future needs of a rapidly evolving weight loss treatment landscape. Metsera was founded in 2022 and is based in New York City. For more information, please visit us at and follow us on LinkedIn and X. Metsera may use its website as a distribution channel of material information about the Company. Financial and other important information regarding the Company is routinely posted on and accessible through the Investors & News section of its website at In addition, you may sign up to automatically receive email alerts and other information about the Company by using the 'Email Alerts' option on the Investors & Media page and submitting your email address. Forward Looking StatementsThis press release includes 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. The Company intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release other than statements of historical fact should be considered forward-looking statements, including, without limitation, statements related to the timelines, design and results of the Company's clinical trials and data releases; the Company's product candidate pipeline and milestone events; potential benefits of treatment with the Company's product candidates; and anticipated market opportunity and strategy. When used herein, words including 'anticipate,' 'believe,' 'can,' 'continue,' 'could,' 'designed,' 'estimate,' 'expect,' 'forecast,' 'goal,' 'intend,' 'may,' 'might,' 'plan,' 'possible,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would' and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. All forward-looking statements are based upon the Company's current expectations and various assumptions. The Company believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. The Company may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, our limited operating history; our ability to generate revenue or become profitable; failure to obtain additional capital when needed on acceptable terms or at all; raising additional capital may cause dilution to our stockholders or require us to relinquish rights to our technologies or product candidates; our dependence on the success of our product candidates; risks associated with preclinical and clinical development; difficulties or delays in the commencement or completion, or the termination or suspension, of clinical trials; our ability to timely enroll patients in our clinical trials; if our current or future product candidates are associated with side effects, adverse events or other properties or safety risks; risks associated with the regulatory approval processes of the FDA and comparable foreign authorities; risks associated with conducting clinical trials and preclinical studies outside of the United States; our reliance on third parties to conduct clinical trials and preclinical studies; our reliance on third parties for the manufacture and shipping of our product candidates; risks associated with our license and collaboration agreements and future strategic alliances; significant competition in our industry; product candidates for which we intend to seek approval as biologic products may face competition sooner than anticipated; our success is dependent on our ability to attract and retain highly qualified management and other clinical and scientific personal; if we or our licensors are unable to obtain, maintain, defend and enforce patent or other intellectual property protection for our current or future product candidates or technology; risks associated with our common stock and the other important factors discussed under the caption 'Risk Factors' in its filings with the Securities and Exchange Commission, including in its Annual Report on Form 10-K for the year ended December 31, 2024 and its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025, which are accessible on the SEC's website at and the Investors section of the Company's website at Any such forward-looking statements represent management's estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause the Company's views to change. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this press release. Contact:Jono EmmettMetseramedia@
